KEMA takes proactive stance on 2003/32 accreditation
This article was originally published in Clinica
Dutch notified body KEMA Quality began its animal tissue Directive (2003/32/EC) accreditation process some three years ago. It found that a good working relationship with the national competent authority led to a relatively smooth and swift conclusion, thereby enabling it to avoid the last-minute panic that has embroiled some NBs and tissue-containing devices as the Directive's effective date of October 1 loomed (see above and Clinica No 1131, p 3)
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.